The global tissue engineering market size was valued at USD 2374 Million in 2019 and is forecasted to reach a size of USD 6815 Million by 2027 at a CAGR of 14.2% from 2020 to 2027. Key drivers of the tissue engineering market include the rising incidences of chronic diseases and trauma emergencies along with awareness regarding tissue engineering therapies.
The technological advancements in 3D bioprinting and R&D activities will fuel the growth of the tissue engineering market in the coming years. Commercialization of tissue-engineered products and spurt in regenerative medicine use will provide huge scope for market expansion. However, high costs, strict government rules, and covid 19 restrictions will hamper the tissue engineering market growth in the subsequent years.
Growing diseases such as diabetes, obesity, trauma cases, and rising awareness levels
Skin loss happens due to a variety of reasons such as diabetes, thermal injuries, chronic ulcer, pressure, venous stasis, etc. Chronic wounds and injuries degrade the quality of life and lead to disability, imbalance, amputation, or even death. People are opting for therapeutic interventions through tissue-engineered skin replacements for restoring functional, structural properties to the affected skin mass. The increasing recognizance of reengineered tissues and organs has helped end the pain of debilitating diseases and wounds. This in turn will drive the growth of the tissue engineering market in the upcoming years.
The emergence of newer technologies
3D printing, skin grafting, bioartificial organs, biomimetics, and materials are the latest technological solutions for accelerating the body’s healing capacity and stimulating regeneration. Several 3D printed constructs and scaffolding equipment have been approved to provide cellular differentiation and reconstruction of wounded body tissues. The rapid innovations and launching of a variety of advanced equipment by key players will continue further accelerating the growth of the tissue engineering market during the review period.
The rise in preference for regenerative medicine and largescale commercialization
Stem cell research and regenerative therapies are gaining traction worldwide. These biomedical and cell research methodologies have the potential to revolutionize the medical industry. They are being applied to regenerate certain body tissues and organs or growing artificial parts in laboratories for completely replacing the original organ. Bones, cartilage, blood vessels, cardiovascular repair, and bladder can be imitated artificially to restore normal functioning. Preventive care also forms an essential part of the regenerative process. Moreover, the rapid commercialization is aiding in the overall growth of the market. These factors will significantly boost the tissue engineering market growth in the future.
Costly and covid 19 impact
There are a host of potential benefits to this industry. But the high research and development costs, lower profit margins, and escalating manufacturing prices will severely restrict the market. It remains out of reach of the majority of the population. Moreover with the ongoing covid 19 pandemic pharmaceutical and biotech companies have shifted their focus to developing covid vaccines and research on possible treatments. All non-essential clinical trials and resource spending has been halted. The stringent government rules further complicate the process. This in turn will restrain the growth of the tissue engineering market in the subsequent years.
Based on type, the biologically derived scaffolding material dominated the market in 2019 and will continue to provide lucrative opportunities for growth in the tissue engineering market share due to its biodegradability, non-toxic, quick cellular matching, and easy functioning process. On the other hand, synthetic materials will grow the fastest due to their effectiveness.
Based on application, the orthopedics and musculoskeletal segment will maintain dominance in the tissue engineering market share due to growing musculoskeletal disorders and the presence of various options such as the spine, bone substitute, graft, cartilage, etc. However, the cardiovascular segment will grow rapidly due to leading innovations and research activities.
Based on region, North America will provide huge growth opportunities in the tissue engineering market share due to developed infrastructure and rising chronic diseases. The Asia-Pacific segment will grow at the highest CAGR of 16.3% due to technological advancements and disorders.
Report Metric |
Details |
Report Name |
Tissue Engineering Market |
Market size value in 2019 |
USD 2,374 Million |
Revenue forecast in 2027 |
USD 6,815 Million |
Growth Rate |
14.2% |
Base year considered |
2019 |
Forecast Period |
2020-2027 |
By Type |
Synthetic Scaffold Material, Biologically Derived Scaffold Material |
By Application |
Orthopedics & Musculoskeletal, Neurology, Cardiovascular, Skin & Integumentary, Dental |
Report Coverage |
Revenue & volume forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered |
By Type, Application, and Region |
Geographic Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Ans. The global tissue engineering market was valued at $2,374 million in 2019, and is projected to reach $6,815 million by 2027, registering a CAGR of 14.2% from 2020 to 2027.
Ans. The key players profiled in this report include AbbVie Inc. (Allergen Plc.), B. Braun Melsungen AG, Becton, Dickinson and Company (C. R. BARD, INC.), Integra LifeSciences, Organogenesis Holdings, Sid Martin Biotech (Axogen), Smith & Nephew Plc. (Osiris Therapeutics), TissueTech Inc.
Ans. Yes, the report includes a COVID-19 impact analysis. Also, it is further extended into every individual segment of the report.
$5769
$6450
$9995
$3840
HAVE A QUERY?
OUR CUSTOMER
SIMILAR REPORTS
Add to Cart
Add to Cart
Add to Cart
Add to Cart